Page last updated: 2024-09-03

gefitinib and Adenoma, Basal Cell

gefitinib has been researched along with Adenoma, Basal Cell in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's6 (85.71)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Collard, TJ; Greenhough, A; Gupta, B; Legge, DN; Morgan, RG; Mortensson, E; Williams, AC1
Feelders, RA; Hofland, LJ; Lacroix, A; Newell-Price, J; Nieman, LK; Pivonello, R1
Hudish, TM; Karoor, V; Keith, RL; Le, M; Miller, YE; Mozer, AB1
Clarke, AR; Maughan, TS; Shaw, PH1
Wondisford, FE1
Ben-Shlomo, A; Bruyette, D; Cooper, O; Fukuoka, H; Mamelak, A; Melmed, S; Ren, SG1
Bissonnette, M; Cerda, S; Cohen, G; Dougherty, U; Fichera, A; Gong, C; Hart, J; Jagadeeswaran, S; Joseph, L; Khare, S; Little, N; Mustafi, R; Sehdev, A; Tallerico, M; Tretiakova, M; Turner, JR; Yuan, W1

Reviews

1 review(s) available for gefitinib and Adenoma, Basal Cell

ArticleYear
Advances in the medical treatment of Cushing's syndrome.
    The lancet. Diabetes & endocrinology, 2019, Volume: 7, Issue:4

    Topics: ACTH Syndrome, Ectopic; ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenal Gland Neoplasms; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cabergoline; Cushing Syndrome; Dopamine Agonists; ErbB Receptors; Gefitinib; Hormones; Humans; Imidazoles; Isoquinolines; Molecular Targeted Therapy; Pituitary ACTH Hypersecretion; Pyrazoles; Pyridines; Receptors, Glucocorticoid; Roscovitine; Somatostatin; Temozolomide; Tretinoin

2019

Other Studies

6 other study(ies) available for gefitinib and Adenoma, Basal Cell

ArticleYear
LGR5 expression is regulated by EGF in early colorectal adenomas and governs EGFR inhibitor sensitivity.
    British journal of cancer, 2018, 02-20, Volume: 118, Issue:4

    Topics: Adenoma; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Disease Progression; Down-Regulation; Drug Synergism; Epidermal Growth Factor; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Protein Kinase Inhibitors; Receptors, G-Protein-Coupled; Wnt Signaling Pathway

2018
Chemoprevention of murine lung cancer by gefitinib in combination with prostacyclin synthase overexpression.
    Lung cancer (Amsterdam, Netherlands), 2010, Volume: 70, Issue:1

    Topics: Adenoma; Animals; Antineoplastic Agents; Cadherins; Cytochrome P-450 Enzyme System; Dinoprostone; Epoprostenol; ErbB Receptors; Female; Gefitinib; Intramolecular Oxidoreductases; Lung Neoplasms; Male; Mice; Mice, Transgenic; Protein Kinase Inhibitors; Quinazolines; Rats; Signal Transduction

2010
Dual inhibition of epidermal growth factor and insulin-like 1 growth factor receptors reduce intestinal adenoma burden in the Apc(min/+) mouse.
    British journal of cancer, 2011, Aug-23, Volume: 105, Issue:5

    Topics: Adenoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Down-Regulation; Drug Evaluation, Preclinical; Drug Synergism; ErbB Receptors; Gefitinib; Genes, APC; Intestinal Neoplasms; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor, IGF Type 1; Tumor Burden

2011
A new medical therapy for Cushing disease?
    The Journal of clinical investigation, 2011, Volume: 121, Issue:12

    Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Animals; ErbB Receptors; Gefitinib; Humans; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines

2011
EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas.
    The Journal of clinical investigation, 2011, Volume: 121, Issue:12

    Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenocorticotropic Hormone; Animals; Cell Line, Tumor; Corticosterone; Dog Diseases; Dogs; Drug Screening Assays, Antitumor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplasm Transplantation; Pituitary ACTH Hypersecretion; Pro-Opiomelanocortin; Promoter Regions, Genetic; Protein Kinase Inhibitors; Quinazolines; Secretory Rate; Tumor Burden

2011
Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis.
    Cancer research, 2007, Jan-15, Volume: 67, Issue:2

    Topics: Adenoma; Animals; Azoxymethane; beta Catenin; Carcinogens; Cell Transformation, Neoplastic; Colonic Neoplasms; Cyclin D1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; ErbB Receptors; Gefitinib; Genes, ras; Male; Mice; Mice, Inbred A; Mutation; Quinazolines; Signal Transduction; Up-Regulation

2007